(Q37695495)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

multicenter clinical trial

13 March 2020

main subject

0 references

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Giuseppe Tonini

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Luca Moscetti

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Paolo Marchetti

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Patrizia Vici

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1

Teresa Gamucci

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Andrea Michelotti

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Laura Pizzuti

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Lucia Mentuccia

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Elisabetta Landucci

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Luigi Di Lauro

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Alessandra Fabi

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Valentina Sini

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Nello Salesi

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Ilaria Ferrarini

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Angela Vaccaro

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Ida Pavese

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Enzo Veltri

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

publication date

20 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

320-327

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.

13 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Treating breast cancer in the 21st century: emerging biological therapies

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Advances in the management of metastatic breast cancer: options beyond first-line chemotherapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Treatment options for breast cancer resistant to anthracycline and taxane

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Eribulin mesylate in heavily pretreated metastatic breast cancer patients: current practice in an Italian community hospital

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Activity of eribulin mesylate in heavily pretreated breast cancer granted access via the Cancer Drugs Fund

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

The place for eribulin in the treatment of metastatic breast cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

A phase II trial of docetaxel and vinorelbine in patients with advanced breast cancer previously treated with anthracyclines

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Reproducibility of research and preclinical validation: problems and solutions.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Vinorelbine and mitomycin C in anthracycline-pretreated patients with advanced breast cancer.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3982178

Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line?

3 December 2018

1 reference

12 December 2020

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

1 reference

12 December 2020

Phase I–II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines

1 reference

12 December 2020

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

1 reference

12 December 2020

Methodology for comparative effectiveness research: potential and limitations

1 reference

12 December 2020

Late lines of treatment benefit survival in metastatic breast cancer in current practice?

1 reference

12 December 2020

Impact of chemotherapy beyond the first line in patients with metastatic breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.7150/JCA.8748

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24723974%20AND%20SRC:MED&resulttype=core&format=json